# Phase I Double-blind, Placebo-controlled Study of AZD7442

> **NCT04896541** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 40 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** AZD7442 300 mg IM(male)
- **BIOLOGICAL:** AZD7442 600 mg IM (male)
- **BIOLOGICAL:** AZD7442 300 mg IV (male and female)
- **BIOLOGICAL:** AZD7442 1000 mg IV (male)

## Key facts

- **NCT ID:** NCT04896541
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-16
- **Primary completion:** 2022-06-14
- **Final completion:** 2022-06-14
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04896541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04896541, "Phase I Double-blind, Placebo-controlled Study of AZD7442". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04896541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*